Empagliflozin Plays Vasoprotective Role in Spontaneously Hypertensive Rats via Activation of the SIRT1/AMPK Pathway
Cells · 2025
DOI: 10.3390/cells14070507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Monika Kloza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, Poland. Hauptthemen laut MEDLINE: Sirtuin 1, Glucosides, AMP-Activated Protein Kinases, Benzhydryl Compounds. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, National Science Centre (Poland).
Abstract (Originalsprache)
Empagliflozin (EMPA), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, prevents endothelial dysfunction, but its effects on vascular tone in hypertension remain unclear. This study investigated whether EMPA modulates vasomotor tone via sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK) pathways in spontaneously hypertensive rats (SHR) and controls (Wistar Kyoto rats, WKY). Functional (wire myography, organ bath) and biochemical (Western blot) studies were conducted on the third-order of the superior mesenteric arteries (sMAs) and/or aortas. EMPA induced concentration-dependent relaxation of preconstricted sMAs in both groups. In SHR, EMPA enhanced acetylcholine (Ach)-induced relaxation in sMAs and aortas and reduced constriction induced by phenylephrine (Phe) and U46619 in sMAs. The SIRT1 inhibitor (EX527) abolished EMPA’s effects on Ach-mediated relaxation and U46619-induced vasoconstriction, while AMPK inhibition reduced Ach-mediated relaxation and Phe-induced vasoconstriction. SHR showed increased SGLT2 and SIRT1 expression and decreased pAMPK/AMPK levels in sMAs. In conclusion, EMPA might exert vasoprotective effects in hypertension by enhancing endothelium-dependent relaxation and reducing constriction via AMPK/SIRT1 pathways. These properties could improve vascular health in patients with hypertension and related conditions. Further studies are needed to explore new indications for SGLT2 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, Poland.
- Department of Clinical Pharmacy, Medical University of Białystok, 15-222 Białystok, Poland.
ORCID-Profile: Monika Kloza, Anna Krzyżewska, Hanna Kozłowska, Sandra Budziak, Marta Baranowska-Kuczko
Förderung
- National Science Center
- National Science Centre (Poland)
Zitieren
APA
Kloza, M., Krzyżewska, A., Kozłowska, H., Budziak, S., & Baranowska-Kuczko, M. (2025). Empagliflozin Plays Vasoprotective Role in Spontaneously Hypertensive Rats via Activation of the SIRT1/AMPK Pathway. Cells. https://doi.org/10.3390/cells14070507
Vancouver
Kloza M, Krzyżewska A, Kozłowska H, Budziak S, Baranowska-Kuczko M. Empagliflozin Plays Vasoprotective Role in Spontaneously Hypertensive Rats via Activation of the SIRT1/AMPK Pathway. Cells. 2025. doi:10.3390/cells14070507
BibTeX
@article{Kloza2025,
author = {Kloza, Monika and Krzyżewska, Anna and Kozłowska, Hanna and Budziak, Sandra and Baranowska-Kuczko, Marta},
title = {Empagliflozin Plays Vasoprotective Role in Spontaneously Hypertensive Rats via Activation of the SIRT1/AMPK Pathway},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14070507}
}
EUVIMED